期刊文献+

托瑞米芬治疗乳腺增生症的实验研究 被引量:3

Effect of Toremifene on hyperplasia of mammary gland
下载PDF
导出
摘要 目的观察托瑞米芬对大鼠乳腺增生及性激素水平的影响。方法用苯甲酸雌二醇每日注射复制动物模型,放免法测定性激素水平,免疫组织化学法分析不同组标本血管内皮细胞生长因子(vascular endothelial growthFactor,VEGF)、微血管密度(microvessel density,MVD)、碱性成纤维生长因子(basic fibroblast growth factor,bFGF)的变化。结果托瑞米芬治疗大鼠乳腺增生总有效率为100%,小叶腺泡数、导管上皮层数、腺体厚度明显变薄(P<0.05),有调节性激素水平的作用,有明显的量效关系。而且托瑞米芬可明显降低大鼠乳腺增生标本VEGF、bFGF、MVD的表达,有明显的量效关系。结论托瑞米芬能不同程度抑制大鼠乳腺增生,明显促进腺体退化,并能调整机体内源性激素水平,还可以降低VEGF、bFGF、MVD的表达,改善乳腺慢性增生的病变过程,达到治疗的目的。 Objective To observe the effect of Toremifene(TOR) on hyperplasia of mammary gland and the blood sex hormones of rat.Methods Benovocylin was injected every day to duplicate animal model.Levels of sex hormone of blood were measured by means of radio-immunoassay.Expressions of vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF) and micro vascular density(MVD) were detected by immunohistochemistry.Results The total efficiency rate of TOR on hyperplasia of mammary gland was 100%.TOR could decrease the number of leaflet acinus,duct epithelial layer and weight of mammary glands.It had a dose-effect relationship in some extent(P〈0.05).TOR could decrease the expressions of VEGF,bFGF and MVD.There was significant dose-effect relationship among different dose of TOR on its effect of the expressions of VEGF,bFGF,MVD.Conclusion TOR can inhibit hyperplasia of mammary glands of rat.TOR can adjust the endogenous sex hormone level,delay the development of chronic serious hyperplasia of mammary gland.TOR can decrease the expressions of VEGF,bFGF,MVD in rats.
作者 孙学民
出处 《同济大学学报(医学版)》 CAS 2009年第2期55-59,共5页 Journal of Tongji University(Medical Science)
关键词 托瑞米芬 乳腺增生病 血清性激素 血管内皮细胞生长因子 碱性成纤维生长因子 微血管密度 Toremifene hyperplasia of mammary gland estrogen progestogen VEGF,bFGF MVD
  • 相关文献

参考文献12

  • 1Harvey HA,Kimura M,Hajba A.Toremifene:an evaluation of its safety profile[J].Breast,2006,15(2):142-157.
  • 2Kusama M,Miyauchi K,Aoyama H,et al.Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer[J].Breast Cancer Res Treat,2004,88(1):1-8.
  • 3Liu Xiao-yan,Fang Hong,Yang Zheng-gang.Matrine inhibits invasiveness and metastasis of human malignant melanoma cell line A375 in vitro[J].Int J Dermatol,2008,47(5):448-456.
  • 4Huang L,Cheng HC,Isom R,et al.Protein kinase cepsilon mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis[J].J Biol Chem,2008,12:7616-7627.
  • 5Curigliano G,Petit JY,Bertolini F,et al.Systemic Effects of Surgery:Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF),Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-beta) in patients with Breast Cancer Who Underwent Limited or Extended Surgery[J].Breast Cancer Res Treat,2005,93(1):35-40.
  • 6黄琴,张清富,陈莉,李姝玉,张楠,明健,邱雪杉.乳腺癌乙酰肝素酶、bFGF、VEGF的表达及其与肿瘤血管生成的关系[J].中国组织化学与细胞化学杂志,2008,17(2):180-185. 被引量:15
  • 7Setyono-Han B,Stürzebecher J,Schmalix WA.Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1[J].Thromb Haemost,2005,93(4):779-786.
  • 8Carrera MP,Ramirez-Exposito MJ,Valenzuela MT,et al.Serum enkephalin-degradeing aminope-ptidase activity in N-methyl nitrosourea-induced rat breast cancer[J].Anticancer Res,2005,25:193-196.
  • 9孙学民,王培军,童晓文.托瑞米芬治疗重症乳腺增生症的临床研究[J].同济大学学报(医学版),2006,27(5):58-61. 被引量:8
  • 10Salama RH,Muramatsu H,Zon P,et al.Mikdine,a heparin-bind2ing growth factor,produced by the host enhances metastasis of lew is lung cancinoma cells[J].Can Lett,2006,233(1):16-20.

二级参考文献27

  • 1贾毅敏,李铜铃,呙临松,李夏.鞣酸苦参碱分散片在人体内的生物等效性[J].华西药学杂志,2008,23(3):303-305. 被引量:9
  • 2于敏,李姝玉,于湛,邱雪杉,侯萍,王恩华,PECKER Iris.肝素酶和碱性成纤维细胞生长因子与非小细胞肺癌转移和预后的关系[J].中华病理学杂志,2005,34(1):36-41. 被引量:15
  • 3Liu XY, Fang H, Yang ZG. Matrine inhibits invasiveness and metastasis of human malignant melanoma cell line A375 in vitro [ J ]. International J dermatol,2008,47 ( 5 ) :448 - 456.
  • 4Jiang T,Zhu Y, Luo C. Matrine inhibits the activity of translation factor eIF4E through dephosphorylation of 4E-BP1 in gastric MKN45 cells [ J ]. Planta medica, 2007,73(11) :1176 - 1181.
  • 5Petridou ET, Chavelas C, Dikalioti SK, et al. Breast cancer risk in relation to most prevalent IgE specific antibodies: a case control study in Greece [ J ]. Anticancer Research,2007,27 ( 3 B ) : 1709 - 1713.
  • 6Mohammad AM,Abdel HA, Abde W, et al. Expression of cyclooxygenase-2 and 12-1ipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors:impact on prognosis and therapy [ J ]. Indian J Cancer, 2006,43 ( 4 ) : 163 - 168.
  • 7Wang Xing, Zhang Wei, Fan Liu-Yin. Sensitive quantitative determination of oxymatrine and matrine in rat plasma by capillary electrophoresis with stacking induced by moving reaction boundary [ J ]. Analytica Chimica Acta, 2007,594 ( 2 ) : 290 - 296.
  • 8Mozaffari F, Lindemalm C, Choudhury A, et al. NK-cell and T-cell functions in patients with breast cancer. effects of surgery and adjuvant chemo-and radiotherapy [ J ]. British J Cancer,2007,97 ( 1 ) : 105 - 111.
  • 9Parr C, Gan CH, Watkins G, et al. Reduced vascular endothelial growth inhibitor expression is associated with poor prognosis in breast cancer patients [ J ]. Angiogenesis, 2006,9 ( 2 ) : 73 - 81.
  • 10中国中医药学会外科乳腺病专业委员会.乳腺增生病诊断、辨证及疗效评价标准[S].2001.121.

共引文献42

同被引文献17

  • 1徐雪松,黄雁萍,邹士林.托瑞米芬治疗乳腺囊性增生症临床疗效的初步观察[J].肿瘤防治杂志,2005,12(4):305-306. 被引量:4
  • 2TEKMAL RR, LIU YG, NAIR HB, et al. Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice [J]. Steroid Biochem Mol Biol, 2005, 95 (1- 5): 9-15.
  • 3KHAN N, MUKHTAR H. Tea polyphenols for health promotion [J]. Life Sci, 2007, 81(7): 519-533.
  • 4YANG CS, WANG X, LU G, et al. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance [J]. Nat Rev Cancer. 2009, 9 (6): 429-439.
  • 5Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med, 1991,324 : 1-8.
  • 6Applanat MP, Buteau-Lozano H, Herve MA, et al. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Bio1,2008, 617:437-444.
  • 7Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect ,2000,108 ( Suppl 5 ) :785-790.
  • 8Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Uro1,2009 ,55 :533-542.
  • 9Garvin S, Nilsson UW, Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-I, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer, 2005,93 : 1005-1010.
  • 10Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen- receptor positive breast cancer. Breast Cancer,2002,9:39-42.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部